Minireviews
Copyright ©The Author(s) 2015.
World J Clin Oncol. Aug 10, 2015; 6(4): 35-42
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.35
Table 1 Comparison of trials investigating chemoradiation for high-risk prostate cancer
Institution/groupnRadiation techniqueComp RxGI toxicityGU toxicityOther toxicity
Continuous infusion 5-fluorouracil
SWOG[29]30Whole pelvis if not surgically negative to 45 Gy + 70.2 Gy 3DCRT to prostate97%Gr 3: 7% Gr 4: 3%Gr 3: 3% Gr 4: 3%Multiple Gr 3: 13% (cumulative)
Daily estramustine phosphate + weekly vincristine
Henry Ford Hospital[36]654-field pelvis to 45 Gy + 65-70 Gy 3DCRT to prostate71%Gr 3: 0% Gr 4: 2%Gr 3: 0% Gr 4: 0%Leukopenia Gr 3: 2%
MSKCC[37]273DCRT to prostate and SV85%Gr 3: 35% Gr 4: 0%Gr 3: 48% Gr 4: 11%Hematologic Gr 3: 8% Liver Gr 3: 7%
Daily estramustine phosphate
Wayne State[39]18Prostate and SV to 50.4-70.2 Gy via 4-field + 3DCRT to prostate 70.2 Gy78%Not reportedNot reportedLeukopenia Gr 3: 12% Venous thrombosis Gr: 6% MI Gr 4: 6%
Weekly docetaxel
UMDNJ[52]223DCRT to prostate to 70.2 Gy100%Gr 3: 9% Gr 4: 0%Gr 3: 0% Gr 4: 0%No Gr 3 or 4
Europe[53]504-field pelvis to 46 Gy + 70 Gy to prostate and proximal SV via 3DCRT or IMRT92%Gr 3: 6% Gr 4: 2%Gr 3: 4% Gr 4: 0%MI Gr 4: 2%
St. Peter’s[70]2072 Gy delivered via IMRT (no further details)85%Gr 3: 0% Gr 4: 0%Gr 3: 0% Gr 4: 0%Dypsnea Gr 3: 5% Dehydration Gr 3: 10%
UNC[72]18Prostate and proximal SV 78 Gy with IMRT89%Gr 3: 11% Gr 4: 0%Gr 3: 0% Gr 4: 0%Leukopenia Gr 3: 28% Liver Gr 3: 6%
Medical University of South Carolina[73]19Prostate and proximal SV 45 Gy + 77.4 Gy prostate with IMRT89%Gr 3: 11% Gr 4: 0%Gr 3: 0% Gr 4: 0%Fatigue Gr 3: 11%
Biweekly Paclitaxel
NYU[64]224-field pelvis to 39.6 Gy + 63-73.8 Gy to prostate and proximal SV via 3DCRT100%Gr 3: 18% Gr 4: 0%Gr 3: 0% Gr 4: 0%No Gr 3 or 4